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Abstract 
Purpose: Compare the efficacy and tolerability of dutasteride in combination with bicalutamide to bicalutamide 
monotherapy in the treatment of locally advanced and metastatic prostate cancer (PCa).
Methods: One-hundred-fifty PCa patients with locally advanced or metastatic disease were prospectively enrolled 
and randomly assigned to receive either bicalutamide monotherapy 150 mg once daily (79 patients) or bicalutamide 
150 mg plus dutasteride 0.5 mg once daily (71 patients). Treatment response was assessed by serum PSA level meas-
urement, and standard procedures for diagnosis of clinical progression were used during follow-up. Patient-reported 
quality of life (QoL) was assessed using validated questionnaires (EORTC QLQ-C30 and QLQ-PR25).
Results: At 3 years follow-up, PSA progression was found in 52 patients [65.8 %; 95 % confidence interval (CI) 55.4–
76.3] in the monotherapy group compared to 38 patients (53.5 %; 95 % CI 41.9–65.1) in the combined therapy group 
(p = 0.134). At the time of analysis 37 men (46.8 %; 95 % CI 35.8–57.8) in the monotherapy group had died versus 30 
men (42.3 %; 95 % CI 30.8–53.7) in the combined therapy group. Median survival time was 5.4 and 5.8 years, respec-
tively (p = 0.694). There was no statistically significant difference in the presentation frequency of adverse events 
between groups (p = 0.683). QoL was good and comparable between the two groups.
Conclusions: Both therapies were well tolerated with a good QoL. However, despite a trend toward higher efficacy 
of the combined therapy, progression-free survival and overall survival was not significantly different between the 
groups. Further research on this therapy should be performed.
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Background
Prostate cancer (PCa) is a major public health problem. 
With 29  % of all newly diagnosed cancers it represents 
the most common cancer among males, and with an 
estimated mortality of 9 % it is the second leading cause 
of cancer related death in this population (Siegel et  al. 
2012).
A rising serum PSA level is generally considered to be 
the earliest evidence of persistent or recurrent disease 
and between 20 and 40 % of men with clinically localised 
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disease will eventually experience biochemical recur-
rence on long-term follow-up after primary treatment 
(Boorjian et  al. 2012; Krygiel et  al. 2005; Vickers et  al. 
2009). This is initially characterised by increasing serum 
PSA levels without radiographic evidence of a local 
recurrent tumour or distant metastases. PSA progression 
often precedes clinical progression and may signal the 
onset of this process (McLaren et al. 1998).
In case of disseminated disease, systemic treatment is 
highly indicated. Standard treatment for these patients 
is androgen deprivation therapy (ADT) using surgical or 
medical castration. The 5-year survival rate of patients 
subjected to ADT is 35 % (Studer et al. 2013). If consid-
erable numbers of PCa patients receive prolonged ADT, 
decreased bone mineral density, increased risk for oste-
oporosis and skeletal fractures can ensue (Serpa Neto 
et al. 2010). Moreover, patients treated with ADT expe-
rience more erectile dysfunction, decreased sexual inter-
est, activity and pleasure, and they report more frequent 
hot flushes in comparison to those not treated with ADT 
(van Andel and Kurth 2003).
Nonsteroidal antiandrogens, such as bicalutamide, 
bind to the androgen receptor and therefore the hypotha-
lamic pituitary axis will not be blocked and testosterone 
levels are unaffected or slightly elevated, resulting in a 
clinical state without the adverse effects of ADT (Ander-
son 2003).
Furthermore, as a 5α-reductase inhibitor inhibits the 
intracellular conversion of testosterone to the more 
potent dihydrotestosterone, it is reasonable to con-
sider that the combination of an antiandrogen and a 
5α-reductase inhibitor should provide an effective form 
of maximal local androgen blockade (Wright et al. 1999).
And since testosterone concentration in plasma sus-
tains, sexual function and quality of life (QoL) could be 
maintained (Iversen 2002). Using non-steroidal antian-
drogens as a first line treatment in patients with local-
ised or metastatic PCa might therefore delay ADT 
side-effects.
In this open-label prospective multicenter randomised 
clinical trial we evaluated the efficacy of bicalutamide 
monotherapy versus bicalutamide plus dutasteride com-
bination therapy on overall survival and PSA progression 
in patients with locally advanced and metastatic PCa. 
Furthermore, the impact of both therapies on QoL was 
assessed.
Patients and methods
In this multicenter study 150 patients were enrolled from 
17 different sites throughout the Netherlands between 
2006 and 2011. All patients had pathologically proven 
PCa and had indication for hormonal treatment, i.e. 
locally advanced or metastatic stage of disease, primary 
or progressive after treatment with curative intent. Addi-
tional eligibility criteria were a PSA level >10  ng/mL, a 
life expectancy of at least 12  months and no previous 
or concurrent chemotherapy or hormonal therapy spe-
cifically for the treatment of PCa. Approval was obtained 
from the Institutional Review Boards in accordance with 
the medical ethical requirements. After giving informed 
consent, patients were randomly assigned into one of the 
two treatment arms. One group received monotherapy 
bicalutamide 150  mg, orally once daily and the other 
group received combined therapy with bicalutamide 
150 mg and dutasteride 0.5 mg, orally once daily.
Treatment response was monitored by serum PSA level 
measurement and biochemical progression was defined 
as an increase in PSA value ≥100 % of the nadir value on 
two separate determinations with an interval of at least 
2  weeks. In case of PSA progression the decision was 
left to the discretion of the urologist, together with the 
patient, to opt for appropriate further treatment.
During follow-up patients underwent physical exami-
nation and assessment for adverse events. Patient-
reported QoL was assessed using the validated European 
Organization for Research and Treatment of Cancer QoL 
core questionnaire (EORTC QLQ-C30) and the Prostate 
Cancer specific module (EORTC QLQ-PR25) (Lintz et al. 
2003). These questionnaires were administered at screen-
ing, every three months thereafter and after 24  months 
annually, until discontinuation of treatment. Various 
pre-specified outcome parameters were extracted from 
these questionnaires, e.g. physical, emotional and social 
functioning, fatigue, pain, urinary/bowel symptoms and 
sexual activity.
Statistical analysis
Sample size was set at 282 patients (141 patients in each 
treatment arm) and calculated to show a difference in 
proportions of patients with PSA progression of 30  % 
in the bicalutamide arm compared to 16  % in the com-
bined treatment arm at 3  years follow-up (power 0.8, 
alpha 0.05). Anticipating a dropout rate of approximately 
15 %, 324 patients were needed. The intended study dura-
tion was 3 years for recruitment and 3 years for follow-
up. The study was discontinued after 4 years due to poor 
recruitment in the predetermined time frame for inclu-
sion. Analysis was based on an intention-to-treat popu-
lation. Statistical significance was assessed using the 
Pearson-Chi square test for proportions and the Wil-
coxon–Mann–Whitney test for continuous variables. 
Overall and progression-free survival was calculated by 
the Kaplan–Meier method and comparison between the 
treatment groups was done by means of the log-rank test. 
Data from the QoL questionnaires were transformed lin-
early to obtain scores from 0 to 100 (Fayers et al. 2001). 
Page 3 of 7Dijkstra et al. SpringerPlus  (2016) 5:653 
QoL comparison of the two groups was done using the 
independent samples T test. Statistical Package for the 
Social Science (SPSS) version 20.0.0.1 was used for 
analysis.
Results
From September 2006 through August 2010 a total of 150 
patients were eligible for participation in the study and 
enrolled for randomisation. 79 patients were assigned 
to the bicalutamide monotherapy arm and 71 patients 
received the bicalutamide and dutasteride regimen. 
Table  1 displays the baseline characteristics of all ran-
domised patients.
At three years follow-up, PSA progression was found 
in 52 patients [65.8 %; 95 %confidence interval (CI) 55.4–
76.3] in the monotherapy group compared to 38 patients 
(53.5  %; 95  % CI 41.9–65.1) in the combined therapy 
(CT) group (p  =  0.134). This results in a difference 
between two independent proportions of 12.3 % (95 % CI 
−3.3−27.2) in favour of the CT group.
At three months of treatment 96.9 % (95 % CI 92.6–100) 
in the monotherapy group and 93.2 % (95 % CI 86.8–99.6) 
in the CT group had >50 % decrease in serum PSA levels. 
However, the mean nadir was significantly lower in the 
CT group compared to the monotherapy group [4.1 ng/
mL (range <0.1–54.0) and 9.3 ng/mL (range <0.1–110.0); 
p < 0.001, respectively]. In the monotherapy group 11.5 % 
(95  % CI 3.5–19.5) reached a non-detectable PSA nadir 
during treatment compared to 39.3 % (95 % CI 26.5–52.1) 
in the CT group.
Median [interquartile range (IQR)] follow-up was 4.1 
(2.0–5.5) years in the monotherapy group and 3.8 (2.0–
5.4) years in the CT group. Sixty-nine (87.3  %; 95  % CI 
80.0–94.7) patients discontinued treatment medication at 
these follow-up intervals in the monotherapy group com-
pared to 55 (77.5 %; 95 % CI 67.7–87.2) in the CT group 
(p = 0.111). Median time to switch to further treatment 
was 1.6 (IQR 0.8–3.1) years versus 1.9 (IQR 0.9–3.9) 
years, respectively. The main reason for discontinuation 
of study medication was biochemical (PSA) progression 
(83.9 %; 95 % CI 77.4–90.3).
At the time of analysis, 67 of 150 patients (44.7 %; 95 % 
CI 36.7–52.6) died, 37 of 79 (46.8 %; 95 % CI 35.8–57.8) 
in the bicalutamide group and 30 of 71 (42.3 %; 95 % CI 
30.8–53.7) in the CT group. No statistically significant 
difference was seen for overall survival between the two 
groups (log rank p = 0.694; Fig. 1a). There was a trend for 
better biochemical progression-free survival in the CT 
group, however, the difference was not statistically sig-
nificant (p = 0.188; Fig. 1b).
Adverse events
In total 108 adverse events were registered for 42 
patients, 21 patients (60 events) in the monotherapy 
group versus 21 patients (48 events) in the CT group. 
Forty-one events (24 versus 17, respectively) were sus-
pected to be related to the study medication. The most 
common adverse events were gynaecomastia (27.9 %) and 
nipple tenderness (18.6  %). Other minor adverse events 
were tiredness/fatigue, constipation, hot flushes and itch. 
There was no significant difference in the frequency of 
adverse events between the study groups (p = 0.683).
Quality of life analysis
At baseline, data on QoL was available from 133 of 150 
patients (89 %); 66 (84 %) in the monotherapy group and 
67 (94 %) in the CT group. On the pre-specified outcome 
parameters no statistically significant differences were 
seen at screening between the two randomised treatment 
groups, except that the bicalutamide group reported 
Table 1 Baseline characteristics of  eligible randomised 
patients
* Pearson Chi square test; † Wilcoxon–Mann–Whitney test
Bicalutamide
(n = 79)
Median  
(range)/n (%)
Bicalutamide +  
dutasteride
(n = 71)
Median  
(range)/n (%)
P
Age, years 71 (54.2–86.1) 73 (54.9–90.7) 0.307†
Baseline PSA  
(ng/mL)
43.4 (11.6–15,000) 46.3 (11.3–660) 0.397†
Clinical stage 0.561*
T1 2 (2.5) 5 (7.0)
T2 12 (15.2) 7 (9.9)
T3 49 (62.0) 47 (66.2)
T4 8 (10.1) 7 (9.9)
Tx 8 (10.1) 5 (7.0)
Metastatic stage 0.746*
M0 45 (57.0) 39 (54.9)
M1 24 (30.4) 26 (36.6)
Mx 10 (12.6) 6 (8.5)
Gleason score 0.767*
≤6 16 (20.3) 12 (16.9)
7 25 (31.6) 28 (39.4)
8 13 (16.5) 12 (16.9)
9 10 (12.7) 7 (9.9)
10 2 (2.5) 0 (0)
Missing 13 (16.5) 12 (16.9)
Primary treatment 0.010*
Radical  
prostatectomy
6 (7.6) 3 (4.2)
Radiotherapy 
treatment
12 (15.2) 27 (38.0)
None 49 (62.0) 36 (50.7)
Missing 12 (15.2) 5 (7.0)
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more urinary symptoms (p = 0.025) (Fig. 2). After three 
and 6 months of treatment 62 (78 %) and 51 (65 %) QoL 
questionnaires were available in the monotherapy group 
and 62 (87 %) and 56 (79 %) in the CT group, respectively. 
At 3 months, patients in the CT group reported signifi-
cantly more treatment related symptoms (hot flushes, 
painful nipples, weight gain/loss) compared to the mono-
therapy group (p =  0.038), however, this difference was 
not seen later and no other significant differences were 
found between the two treatment groups at any other 
timepoint (Fig. 2).
Functional QoL scales scored over 80 % in both groups, 
reflecting a high level of functioning on physical, emo-
tional and social level. General QoL at baseline, 3, 6 and 
12 months was maintained 76, 80, 78, 79 % in the bical-
utamide group and 81, 78, 78, 82  % in the CT group, 
respectively. Sexual activity was scored 78 and 76  % at 
6 months and 81 and 80 % at 12 months in the bicaluta-
mide and CT group, respectively.
Discussion
In this study we aimed to assess and compare the effi-
cacy of bicalutamide monotherapy and bicalutamide plus 
dutasteride treatment in patients with locally advanced 
and metastatic PCa.
The number of patients to be recruited according to 
the sample size calculation was not reached and due 
to poor recruitment in the predetermined time frame 
for inclusion the study was aborted at the time of 150 
enrolled patients. Nevertheless, the calculated difference 
of PSA progression between the groups at 3 years follow-
up was 12.3 % (95 % CI −3.3–27.2) in favour of the CT 
group. This might be assigned to the added 5α-reductase 
inhibitor, however, due to the fact that the study was 
underpowered and the difference was not statistically sig-
nificant, this assumption remains questionable.
Long-term follow-up studies demonstrated the benefit 
of bicalutamide on progression-free survival, whereas 
various other studies showed the efficacy of dutasteride 
in reducing the risk of incident PCa detection in patients 
at risk for PCa, reducing PCa progression in men with 
low-risk disease at active surveillance and reducing bio-
chemical progression in patients with biochemical failure 
after radical therapy (Iversen et al. 2006, 2010; Andriole 
et al. 2010; Fleshner et al. 2012; Schroder et al. 2013).
Rationally it was reasonable to contemplate that add-
ing a 5α-reductase inhibitor to the treatment with a 
pure antiandrogen such as bicalutamide should provide 
an effective form of maximal local androgen blockade. 
Monk et  al. demonstrated the feasibility of combining 
flutamide and finasteride treatment and showed its effi-
cacy regarding PSA response in a cohort consisting of 99 
patients with a rising PSA after definitive local therapy 
(Monk et  al. 2012). In a comparable study, Baňez et  al. 
investigated the efficacy of the combination therapy flu-
tamide plus finasteride compared to low-dose flutamide 
monotherapy in 56 men with biochemical recurrence 
after definitive therapy for PCa (Banez et al. 2009). How-
ever, after a median follow-up of 4.1 years they were not 
able to demonstrate a significant difference in biochemi-
cal progression-free survival between the two treatment 
arms. Nevertheless, on multivariate analysis, men on CT 
Fig. 1 Kaplan-Meier estimates of overall survival (a) and biochemi-
cal progression-free survival (b) in the bicalutamide group and the 
bicalutamide plus dutasteride group
Page 5 of 7Dijkstra et al. SpringerPlus  (2016) 5:653 
had a significantly lower risk of progression compared to 
men on monotherapy (Banez et al. 2009).
Since in these studies the lesser potent selective 
5α-reductase inhibitor finasteride was used, we expected 
to find similar or even better results in our study. Yet, the 
fact that no significant benefit had been found in terms 
of biochemical progression-free survival or overall sur-
vival might be explained by the fact that our study was 
underpowered. Another explanation might be sought in 
the fact that our study consisted of patients with a high 
baseline PSA level (median 43.5  ng/mL), at least 33  % 
of patients was diagnosed with distant metastases and 
a majority had not undergone primary treatment with 
curative intent (64  %). This might indicate a more high 
risk patient cohort compared to the earlier mentioned 
study of Baňez et al.
In contrast to surgical castration and ADT, serum tes-
tosterone levels remain above castration levels in patients 
on antiandrogens and/or 5α-reductase inhibitor treat-
ment, and thus sexual function and QoL will be better 
preserved. In this study we showed that patients in both 
groups had high levels of social functioning, sexual func-
tioning and general QoL throughout the entire study. Our 
findings are confirmed by a study by Prezioso et al. This 
group showed an advantage of antiandrogen treatment 
compared to ADT, delaying ADT related side effects. 
Moreover, antiandrogen monotherapy was associated 
with a significantly better QoL on almost all functional 
scales compared to ADT (Prezioso et  al. 2007). Since 
patients may require many years of treatment, tolerability 
and QoL are of increasingly importance when selecting 
the most appropriate hormonal therapy.
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Fig. 2 Quality of life outcome in both groups on five functional scales (physical, emotional, social, sexual functioning and general quality of life) 
and six symptom scales (nausea, pain, urinary, bowel and treatment related symptoms) at screening, 3, 6 and 12 months of treatment. A high score 
for general quality of life or a functional scale reflects a high QoL or a high level of functioning, whereas a high score for a symptoms scale implies a 
high level of symptoms
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In our study, only a few treatment related adverse 
events were registered. Median time patients stayed on 
treatment medication before further treatment was initi-
ated, was 1.8 years (22 months), which is comparable to 
the time that patients on ADT develop progressive dis-
ease. In a previous study by Tay et  al., 86  % of patients 
remained responsive to subsequent LHRH agonists after 
earlier bicalutamide plus a 5α-reductase inhibitor treat-
ment, indicating that this treatment as primary hormonal 
therapy for advanced PCa probably may not compromise 
the overall duration of the androgen-responsive disease 
(Tay et al. 2004). Since no data was available on further 
treatment, unfortunately we were not able to confirm this 
finding in our study.
Although a recent Cochrane review demonstrated the 
inferiority of anti-androgen monotherapy compared to 
ADT or surgical castration in overall survival and clinical 
progression, earlier mentioned studies on antiandrogen 
combination therapy showed promising results (Monk 
et al. 2012; Banez et al. 2009; Kunath et al. 2014). Moreo-
ver, side-effects of antiandrogen therapy might be more 
favourable compared to (medical or surgical) castration, 
however, a head-to-head comparison was not performed 
in this study. And despite a trend toward higher efficacy 
of the combined therapy was recognised, this study was 
not able to demonstrate a significant difference in efficacy 
between bicalutamide monotherapy and bicalutamide 
plus dutasteride combined therapy. Therefore, further 
research on this therapy should be performed.
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